AMIStem-H Radiological Assessment
Launched by MEDACTA INTERNATIONAL SA · Apr 20, 2018
Trial Information
Current as of May 22, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients who underwent total hip arthroplasty at the investigational sites between April 2009 and April 2012
- • patients bearing an AMIStem-H cementless femoral stem
- Exclusion Criteria:
- • patients who refuse to give consent for the treatment of data
About Medacta International Sa
Medacta International SA is a leading global medical device company specializing in innovative orthopedic solutions, particularly in the fields of joint replacement and minimally invasive surgery. Founded in 1999 and headquartered in Switzerland, Medacta is committed to advancing patient care through cutting-edge technologies and comprehensive educational programs for healthcare professionals. The company’s robust portfolio includes proprietary implants and instrumentation designed to enhance surgical outcomes and improve patient quality of life. With a strong emphasis on research and development, Medacta actively engages in clinical trials to validate the efficacy and safety of its products, positioning itself as a trusted partner in the orthopedic community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bois Guillaume, , France
Paris, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials